Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3'-O-methyltaxifolin is a methylated flavonoid derivative isolated from plants such as *Pulicaria jaubertii*. It is a structural analog of taxifolin (dihydroquercetin) and has been investigated for its potential antineoplastic properties. In vitro studies on colon cancer cell lines (HCT-116) indicate that the compound can induce apoptosis, characterized by chromatin condensation, nuclear shrinkage, and the upregulation of caspase-3 and caspase-9. Molecular docking simulations suggest that its mechanism of action may involve binding to pro-apoptotic and anti-apoptotic proteins, including Bcl-xl and JAK2, thereby modulating cell survival and proliferation pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3'-O-methyltaxifolin.